Analysts have revised their price target for Cohance Lifesciences downward from ₹1,170.63 to ₹930.00. This change reflects updated expectations for lower profit margins and slightly reduced revenue growth projections.
What's in the News
- Dr. V Prasada Raju resigned as Managing Director effective October 28, 2025. He will remain with the company during the transition period (Key Developments).
- The board meeting is scheduled for November 12, 2025, to review and approve unaudited financial results for the quarter and half year ending September 30, 2025 (Key Developments).
Valuation Changes
- The consensus analyst price target has fallen significantly, from ₹1,170.63 to ₹930.00.
- The discount rate has risen slightly, from 12.73% to 12.76%.
- Revenue growth forecasts have been reduced modestly, from 60.80% to 59.10%.
- Net profit margin projections have decreased, from 24.99% to 21.68%.
- The future P/E multiple has edged down, from 59.87x to 58.91x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.